Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Dtil save search
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
TGTX | News | $14.0 1.3% 1.29% 3.5M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
cd19 license cell treatment global commercialization program therapeutics agreement therapy
Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
Published: 2022-11-28 (Crawled : 18:00) - precisionbiosciences.com
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: -0.71%
H: 2.88%
C: -2.88%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.05%
H: 0.89%
C: -0.6%
pbcar0191 t-cell
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: -2.88%
H: 3.7%
C: 3.7%
cd19 meeting presentation
Global Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities
Published: 2022-08-12 (Crawled : 14:20) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.51%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.61%
H: 0.9%
C: 0.73%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.16%
H: 1.53%
C: 1.33%
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 0.61%
H: 23.78%
C: 22.56%
PSTX | News | $2.005 -1.72% -1.75% 520K
|
Health Technology
|
| O: -1.7%
H: 12.62%
C: 8.91%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.42%
H: 0.45%
C: 0.4%
CABA | $13.96 -7.86% -8.52% 1.1M
|
Health Technology
|
| O: 2.76%
H: 4.7%
C: 2.68%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 3.58%
H: 1.99%
C: -1.41%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.07%
H: 0.54%
C: -0.05%
global report funding therapy market
Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-Cell Malignancies
Published: 2022-01-07 (Crawled : 19:00) - precisionbiosciences.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
| Email alert
Add to watchlist
pbcar0191 car-t cel t-cell
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: -2.04%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer arcus car-t t-cell
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
Published: 2021-07-01 (Crawled : 12:00) - biospace.com/
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 1.04%
H: 1.74%
C: 0.08%
phase 1 trial car-t
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
Published: 2021-01-25 (Crawled : 12:01) - globenewswire.com
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 5.49%
H: 0.07%
C: -5.21%
patent car-t application
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
Published: 2021-01-19 (Crawled : 12:03) - globenewswire.com
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 9.91%
H: 18.6%
C: 17.87%
fda fda acceptance car-t
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Published: 2020-12-04 (Crawled : 15:00) - biospace.com/
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: -4.69%
H: 2.36%
C: -14.82%
positive results leukemia trial phase 3 phase 1 phase 2 t-cell
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.